OVID

2.2055.77%
JA

Jeffrey A. Rona

Independent Director

Mr. Jeffrey A. Rona, also known as Jeff, is Independent Director at S&W Seed Company since December 2023. He served as Chief Business and Financial Officer at Ovid Therapeutics Inc. since June 2, 2021 until July 6, 2026 and was its Chief Business Officer since September 2020 until July 6, 2026 and served as its Corporate Secretary until July 6, 2026 and provides advisory services to the Company through December 31, 2027. Prior to joining Ovid Therapeutics, he was the Western region Managing Director for Danforth Advisors, a life science financial strategy consultancy. He served as Chief Business Officer at Ovid Therapeutics Inc until June 2, 2021. He served as the Chief Financial Officer of Great Basin Scientific, Inc. from October 8, 2014 to October 6, 2017. Mr. Rona served as Financial Consultant at Great Basin Scientific, Inc. from 2013 to October 8, 2014. He served as the Managing Director of Rona Capital, LLC, a life sciences-focused transactional advisory consultancy, since 2011. He served as Chief Business Officer of GlobeImmune, Inc from 2006 to 2011. He served as Vice President of Corporate Development for Corgentech, Inc. He served as the Chief Financial Officer of Algorx Pharmaceuticals Inc. from 2003 to 2006 and Anesiva, Inc. since February 2004 and was responsible for the execution of the merger with Corgentech. He served as Vice President of Finance of Anesiva, Inc. from September of 2002 to February of 2004 and served as its Principal Accounting Officer. Prior to joining Algorx Pharmaceuticals Inc as Chief Financial Officer., He was in the Investment Banking Department at UBS Warburg, a global securities and investment banking firm, from 2000 to 2002. From 1998 to 2000, He served as the Director of Finance and Corporate Development at Antigenics Inc., a biotechnology firm developing products to treat cancer, infectious diseases and autoimmune disorders. He has experience as an investment banker, Chief Business Officer and Chief Financial Officer in the life sciences. He has experience in originating, structuring and executing corporate transactions and financings. In 1998, he was employed by Carr & Company, a private equity firm. From 1990 to 1997, He was with Coopers and Lybrand and its wholly-owned subsidiary Coopers & Lybrand Securities, serving in a variety of capacities. He received a B.S. in Accounting from Case Western Reserve University in 1990.

Positions